Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN
This article was originally published in The Pink Sheet Daily
Executive Summary
Ability of novel anticoagulants to capture an extra indication in acutely ill patients currently treated with blockbuster Lovenox is now in doubt.
You may also be interested in...
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.
Apixaban Study Halted - But It May Not Cause Much Damage To The Program
The APPRAISE-2 trial was stopped due to excess bleeding. But the study tested the drug as an add-on treatment in a high-risk population and in a marginal indication for the anticoagulant.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.